AIGH Capital Management LLC Sells 1,907,221 Shares of Biodesix, Inc. (NASDAQ:BDSX)

AIGH Capital Management LLC reduced its stake in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 30.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,272,591 shares of the company's stock after selling 1,907,221 shares during the period. Biodesix comprises 1.1% of AIGH Capital Management LLC's investment portfolio, making the stock its 25th biggest position. AIGH Capital Management LLC owned approximately 2.92% of Biodesix worth $2,671,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of BDSX. Barclays PLC boosted its holdings in Biodesix by 387.3% in the 4th quarter. Barclays PLC now owns 112,254 shares of the company's stock worth $171,000 after buying an additional 89,218 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in Biodesix by 385.9% in the 4th quarter. Cubist Systematic Strategies LLC now owns 51,024 shares of the company's stock worth $78,000 after buying an additional 40,524 shares during the period. Samjo Management LLC bought a new position in Biodesix in the 4th quarter worth approximately $3,790,000. Northern Trust Corp boosted its holdings in Biodesix by 286.5% in the 4th quarter. Northern Trust Corp now owns 169,132 shares of the company's stock worth $259,000 after buying an additional 125,368 shares during the period. Finally, Susquehanna International Group LLP boosted its holdings in Biodesix by 769.8% in the 4th quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company's stock worth $1,707,000 after buying an additional 987,475 shares during the period. 20.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Scotiabank lowered their target price on shares of Biodesix from $3.00 to $2.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, May 21st. Canaccord Genuity Group lowered their target price on shares of Biodesix from $2.50 to $1.50 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Lake Street Capital lowered their target price on shares of Biodesix from $3.00 to $2.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. William Blair reiterated a "market perform" rating on shares of Biodesix in a research note on Wednesday, May 14th. Finally, Craig Hallum lowered their target price on shares of Biodesix from $3.00 to $1.50 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1.75.

Biodesix Price Performance

Shares of Biodesix stock traded up $0.00 on Friday, hitting $0.42. 1,026,765 shares of the company traded hands, compared to its average volume of 4,274,988. The firm's 50-day simple moving average is $0.31 and its 200 day simple moving average is $0.62. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 3.32. The company has a market cap of $61.70 million, a P/E ratio of -1.45 and a beta of 0.97. Biodesix, Inc. has a 12-month low of $0.17 and a 12-month high of $2.04.

Biodesix (NASDAQ:BDSX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). Biodesix had a negative net margin of 54.28% and a negative return on equity of 167.28%. The company had revenue of $17.96 million for the quarter, compared to analysts' expectations of $19.50 million. Analysts expect that Biodesix, Inc. will post -0.35 earnings per share for the current fiscal year.

Biodesix Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.